The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
Clinical Trial Club | Current clinical landscape in anemic myelofibrosis
Featured:
Jean-Jacques KiladjianVideo series
On February 26, 2024, Scientific Education Support hosted a Clinical Trial Club entitled “Treatment sequencing for anemic myelofibrosis.” This live webinar was part of the MPN Hub Clinical Trial Club webinar series, “Novel agents for the treatment of anemic myelofibrosis.”
The webinar reviewed the current clinical landscape of myelofibrosis, optimal treatment sequencing, and key data from recent clinical trials, including COMFORT-1 and COMFORT-2, JAKARTA, SIMPLIFY-1 and SIMPLIFY-2, and MOMENTUM. The event was chaired by Jean-Jacques Kiladjian, Université de Paris - Hôpital Saint-Louis, Paris, FR, who was joined by fellow expert, Angela Fleischman, University of California, Irvine, US.
Kiladjian began by outlining the current NCCN treatment guidelines for anemic myelofibrosis and the impact of cytopenias. He then explored current treatment challenges and unmet needs, before briefly reviewing the recent approval of momelotinib.
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
More from this series:
